Importantly, at an individual-trial level some randomized clinical trials, including the CANDLE trial, showed that short-term treatment with SGLT2 inhibitors had a neutral effect on natriuretic peptide concentrations even in patients with established HF [33]. The gene discussed is SLC5A2; the disease is hydrops fetalis.